CPA
ALIM

Columbia Pacific Advisors’s Alimera Sciences ALIM Stock Holding History

Columbia Pacific Advisors’s Portfolio ALIM Stock Details ALIM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-3,365
Closed -$45K – 13
2019
Q2 		$45K Hold
3,365
– – 0.15% 19
2019
Q1 		$54K Buy
+3,365
New +$51.2K 0.13% 28

Other funds holding ALIM

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Columbia Pacific Advisors's ALIM Position: Q3 2019 in Review

Columbia Pacific Advisors sold out of Alimera Sciences (ALIM) in Q3 2019, closing a stake of 3,365 shares — an estimated $45K sold.

Columbia Pacific Advisors first reported a position in ALIM in Q1 2019 and held it in 2 quarters. The position peaked at $54K in Q1 2019. 32 funds tracked by Wall St. Rank hold ALIM as of Q3 2019.

  • Columbia Pacific Advisors reported no remaining Alimera Sciences position as of Q3 2019 after selling out during the quarter.
  • Columbia Pacific Advisors sold 3,365 Alimera Sciences shares in Q3 2019, an estimated $45K.
  • Columbia Pacific Advisors first reported a position in Alimera Sciences in Q1 2019 and held it in 2 quarters.
  • Columbia Pacific Advisors's Alimera Sciences position peaked at $54K in Q1 2019.
  • 32 funds tracked by Wall St. Rank held Alimera Sciences as of Q3 2019.

Based on Columbia Pacific Advisors's 13F filing for Q3 2019, filed 13 Nov 2019.